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1. Introduction
In May 2017, 24 people from 13 countries attended the
231st European Neuromuscular Center (ENMC) workshop
in Naarden, The Netherlands, to provide an international
standard for chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP) registries and biobanks. The
group included researchers and clinical experts in inflammatory
neuropathies, experts in neurophysiology and nerve pathology,
three young researchers, and a patient representative from the
patient organisation “Spierziekten Nederland” and GBS/CIDP
Foundation International.
CIDP is a remarkably heterogeneous disorder including
various atypical clinical phenotypes [1–5]. It is unclear whether
the typical and atypical phenotypes share the same pathogenesis.
Furthermore, despite various sets of diagnostic criteria [6–9],
not all patients are yet identified, as there are reports of response
to treatment in patients not fulfilling the current clinical and/or
electrophysiological criteria [10]. Supportive diagnostic tests
such as lumbar puncture, imaging and nerve biopsy can help in
providing additional evidence for the diagnosis CIDP, but their
diagnostic value has not been systematically assessed.
Corticosteroids, intravenous immunoglobulin (IVIg) and
plasma exchange are proven effective short-term treatments for
CIDP, as summarised in Cochrane reviews [11–13].
Nevertheless, the choice of first-line treatment is primarily
driven by patient’s and physician’s preferences as these
treatments in general have comparable effects. Some patients
show a monophasic and short disease course, while others have
a relapsing-remitting or a chronic progressive course requiring
regular maintenance treatment. During maintenance treatment,
the optimal dose and interval of the chosen regimen is mainly by
n = 1 experiments, since evidence-based strategies to optimize
the treatment in individual patients have not been defined. There
is a lack of biomarkers to monitor disease activity, which in
combination with the highly variable clinical course makes it
very hard to determine treatment duration and timing of
withdrawal attempts.
2. Objectives of an international CIDP registry and aims
of the ENMC workshop
Further research is needed to define the diagnostic clinical and
electrophysiological boundaries of CIDP and its subtypes, and to
define the role of biomarkers in supporting the diagnosis,
monitoring disease activity and predicting response to treatment
and outcome. Ideally, the choice of treatment should be based on
a personalized profile including clinical, electrophysiological and
biological characteristics that accurately predicts which treatment
and regime will be most effective in a specific patient. More
specifically, an international CIDP registry should provide
information to fulfil the following objectives:
- Define variation of CIDP phenotypes and subtypes
- Improve diagnostic criteria
- Evaluate and improve clinimetrics
- Long-term treatment outcome and pharmacovigilance
- Develop a prediction model of treatment response and
outcome
- Find biomarkers to support the diagnosis and monitor
disease activity and treatment
response
- Standardise the registry of patients and the collection of
biomaterials to allow studies on pathogenesis and
development of new treatment
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Several national registries and biobanks have been
developed recently to enable systematic data collection in
CIDP. However, even in large countries, these registries will not
be able to include a sufficient number of patients to address the
most important challenges described above. An international
registry with large number of patients is needed to allow
validation of prognostic models to predict outcome in
individual patients with CIDP. During a debate on national
databases at the Inflammatory Neuropathy Consortium (INC)
meeting at Glasgow (June 2016), the need for international
collaboration was once again emphasized, and the intention was
laid out that centres could join existing database initiatives and
that existing databases should be able to exchange data to a
central database. The INC members agreed that an ENMC
workshop would be the ideal setting to reach a consensus on the
collection of a core set of clinical and diagnostic data and
metadata, on the biomaterials, and on the infrastructure of
databases and biobanks.
2.1. Aims of the ENMC workshop
2.1.1. Primary objectives
- Consensus on inclusion and exclusion criteria
- Core set of clinical data, diagnostic data and follow-up
points including outcome measures
- An optional but recommended set of clinical data, diagnostic
data and follow-up points
- A manual of operations for the collection of biomaterials
2.1.2. Secondary objectives
- A metadata dictionary
- Agreement on type of database(s)
- A timeline of merging data from existing databases
- Agreement on the infrastructure of coordinating centres
- Agreement on the governance of this initiative
- Proposals on ownership, publications, data sharing and
biomaterial sharing
3. Preparations of workshop
Prior to the workshop coordinators of current CIDP
registries were asked to fill in a questionnaire providing details
on infrastructure, governance, inclusion and exclusion criteria,
and collected clinical and diagnostic data. Details on collected
biomaterials including storage conditions were noted. The
questionnaires included details on used databases, software and
possibilities to share the data.
4. Clinical data
4.1. Overview of clinical data from current registries
After a short introduction on the objectives of CIDP
registries, representatives of five currently running registries
provided a brief overview of their registries. More details on
selection of patients, collected clinical data during baseline and
follow-up, time points of follow-up were provided by Filip
Eftimov in a comparison matrix of eight current registries (Italy,
The Netherlands, Spain, France, Germany/Norway/India,
Japan, Serbia/Montenegro and Belgium). Most registries were
national and included CIDP patients only. All registries use the
EFNS/PNS criteria for CIDP [6], but many allow inclusion of
patients with suspected CIDP. The eight registries altogether
have included over 1300 CIDP patients, with the majority being
prevalent cases. Carina Bunschoten and Eduardo Nobile-
Orazio provided an in-depth comparison between the Dutch
pilot registry (International CIDP Outcome Study or ICOS) and
the Italian registry, illustrating the similarities between the two
registries. Furthermore, they also suggested a minimal baseline
clinical data set.
The registries have different levels of complexity in terms of
extensiveness of clinical data, diagnostic data entered at
baseline and follow-up, and the collection of biomaterials. The
Dutch, Italian and Japanese registries were considered the most
extensive, being able to address all objectives mentioned above.
However, it was recognized that these registries would be too
burdensome for all eligible centres, as they require an extensive
infrastructure, especially when considering fixed follow-up
visits and biomaterial collection at each visit. In this report we
will focus on the core data that can be collected by all centres
(level 1 complexity). This core data will enable to address the
following objectives:
1) Define variation of CIDP phenotypes and subtypes;
2) Improve diagnostic criteria;
3) Define the long-term treatment outcome;
4) Develop a prediction model of treatment response and
outcome; and
5) Allow studies on pathogenesis based on collected
biomaterials at baseline.
In addition, suggestions were made to harmonize data
collection of more complex registries (level 2 complexity), that
could address specific objectives such as risk factors for
development of CIDP, improving clinimetrics, finding
biomarkers of disease activity and pharmacovigilance of CIDP
treatments.
4.2. Consensus on minimal baseline clinical data
At baseline, most registries include questions on symptoms
and details from neurological examination to allow adequate
description of the clinical phenotype. It was debated that the
distinction between these phenotypes is more or less arbitrary
and it is not yet clear whether making of this distinction is
clinically important. Sensitivity of the EFNS/PNS criteria was
generally regarded as suboptimal to detect all inflammatory
neuropathies responding to treatment, especially those with
pure sensory involvement. Therefore a consensus was reached
that a CIDP registry should include all patients with the
clinical suspicion of CIDP. The presence of detailed baseline
data is needed to allow detailed clinical and electrophysiologal
phenotyping of these patients to provide a better description of
the CIDP boundaries but also to improve diagnostic criteria. It
was also concluded that primary focus should be on CIDP, but
inclusion of other chronic inflammatory neuropathies in
the future should be considered after reaching a consensus on
the infrastructure of the global registry. Registries should
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include questions on which diagnoses were considered and/or
excluded, following the recommendations of the EFNS/PNS
guideline.
Further, in-depth comparison on how questions and answer
options are formulated is needed to further harmonize protocols
and to improve data comparison between registries. Summary
of mandatory core baseline data on history and symptoms is
provided in Table 1. Some of the more complex registries (level
2) will also include questionnaires to address possible
association with developing CIDP.
4.3. Consensus on outcome measures at baseline and
follow-up visits
Ingemar Merkies provided an update on outcome measures
in CIDP [14]. To minimise burden of extensive follow-up visits,
he suggested choosing one or two measures representing each
outcome level of assessment, in essence at the impairment,
activity and participation, and quality of life. Grip strength is
generally considered as the most responsive outcome measure
and should be used with preference given to the handheld
dynamometer Martin Vigorimeter as the preference choice by
CIDP patients. It was also recognized that in some patients (for
example patients with gait ataxia as dominant symptom) grip
strength might not be the most informative outcome measure.
Therefore it was concluded that in addition to grip strength,
treating physician should chose an impairment scale considered
relevant for the individual patient. At activity and participation
level, he suggested including the inflammatory Rasch Overall
Disability scale (I-RODS) and the INCAT disability scale, the
latter based on its use in various international trials as suggested
by regulatory agencies. The EuroQol is a short questionnaire to
measure quality of life and is suitable to use as health outcome.
Finally, it was discussed to which level other patient-reported
outcome measures (PROMs) should be used. As fatigue is a
frequent complaint of CIDP patients, it was suggested that a
(Rasch-built) fatigue severity scale (FSS) should be included.
The minimal outcome measures used at baseline and follow-up
visits are summarised in Table 1 (level 1).
More extensive registry protocols will include different
impairment outcome measures and some already include
more PROMs (level 2). This will provide important data to
assess and improve the clinimetric value of existing outcome
measures, and can help in the development of new outcome
measures.
4.4. Consensus on minimal follow-up visits
Complex registries have follow-up visits at fixed intervals,
with extra visits in case of a newly diagnosed patient, an
unstable disease course or deterioration. It was also argued that
this could prove difficult for all participating centres in which
some patients are seen only occasionally due to large travel
distances. Alternatively, some form of follow-up was judged
necessary for various reasons, especially for verifying the
diagnosis of CIDP. Patricia Blomkwist pointed out that long-
term follow-up is very important to patients with a chronic
disease and registries should address this. Several registries
prespecified a minimum follow-up of two years, but some also
regarded two years as too short.
Follow-up visits are therefore recommended for a minimum
of 2 years and preferably as long as the disease is active. Visits
may be scheduled at clinician’s discretion, based on disease
activity and health care infrastructure. Complex registries
coordinators indicated that they would continue to use fixed
intervals and additional visits if necessary that will provide
more precise data on outcome and biomarkers of disease
activity (level 2).
In addition to the outcome measures suggested above,
follow-up visits should assess whether diagnosis has been
changed and provide data on changes in treatment including
tapering and/or withdrawal of treatment (level 1). Standardised
questionnaire on adverse events of treatments could be used for
pharmacovigilance (level 2).
Table 1
Core clinical data at baseline and follow-up.
Level 1 complexity Level 2 complexity
(in addition to level 1)
Inclusion of patients Clinical suspicion of CIDP
Baseline data - Epidemiological data












- Patient specific impairment measure(s) (at discretion of physician)
- MRC-SS
- INCAT-SS
- Numeric pain intensity rating scale
Follow-up visits At clinician’s discretion, minimal follow-up of 2 years recommended Fixed visits and extra visits dependent on disease course
Follow-up data Treatment changes Registration of adverse events
Abbreviations: I-RODS = Inflammatory Rasch-built Overall Disability Scale; INCAT-SS = Inflammatory Neuropathy Cause and Treatment Sensory sum score;
R-FSS = Rasch-built Fatigue Severity Scale; MRC-SS = Medical Research Council sum score.
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5. Diagnostic data
5.1. Introduction to diagnostic tools in CIDP
Peter Van den Bergh provided an overview of the
electrophysiological EFNS/PNS criteria for CIDP that have the
highest diagnostic accuracy for the diagnosis of CIDP.
Nevertheless, some patients with CIDP are not identified
with these criteria while others are misdiagnosed. Some
electrophysiological features could be used as predictor of
treatment response, of which signs of extensive axonal damage
is probably the most reliable predictor for lack of treatment
response. Alternatively, the value of nerve conduction studies
(NCS) as outcome measure during follow-up was considered of
limited value by most participants and not practical for
registries. Van den Bergh also illustrated that standardisation of
NCS protocols remains an important problem. In some recent
randomized controlled trials, tested nerves and stimulation sites
were standardised, but it was questioned whether this is feasible
for a registry in which laboratories of participating centres have
different protocols and NCS are not routinely repeated.
Antonino Uncini followed by explaining how difficult it is to
combine data from NCS studies in a single registry, as data
cannot be transferred from NCS software to other databases.
Manual entry of each value is currently needed which is
extremely time consuming and prone to mistakes in data entry.
Stephan Goedee provided encouraging data on the role of
ultrasound in the diagnosis of CIDP, which is not yet part of the
diagnostic CIDP guideline. He also illustrated the varying
results of the diagnostic value of MRI in supporting the
diagnosis CIDP and suggested to consider including ultrasound
as part of the diagnostic criteria for CIDP in the future.
Finally, Jean-Michel Vallat explained that nerve biopsy
could be very valuable in patients not meeting the current
diagnostic criteria for CIDP. One of the challenges of including
nerve biopsy in a registry is the lack of standardised protocols
for preservation and examination of nerve tissue. There are
several techniques that can be used to study nerve pathology,
and it was suggested that paraffin and epon embedding (semi-
thin sections) are at least required to study nerve pathology. For
the description of the pathologic abnormalities he suggested a
qualitative and where possible a semi-quantitative (categorical)
approach to describe 1) presence of inflammatory cells; 2)
lesions of myelinated fibres; 3) lesions of unmyelinated fibres
and 4) lesions of other types.
5.2. Overview of diagnostic data from current registries
After the introduction of the different diagnostic techniques,
Yusuf Rajabally (YR) provided a comparison of the eight
registries on diagnostic data. Diagnostic data was used in six
registries, with variable number of diagnostic modalities being
used. NCS studies and CSF results were collected in most
registries. In four registries NCS protocol was prespecified but
only in the Japanese registry a standardised NCS protocol was
mandatory. It was concluded that there was considerable
heterogeneity in NCS practice and data collection among
countries with CIDP registries. YR emphasized that there are
many practical issues that should be addressed prior to
comparing data from NCS studies, such as standardising distal
distances, definition of compound muscle action potential
(CMAP) amplitudes and duration and body temperature.
Another challenge is the upload of data into database as
previously mentioned by Uncini.
5.3. Consensus/recommendations on diagnostic data
There was a consensus that meeting NCS criteria should be
mentioned and if so, whether definite, probable or possible criteria
were also fulfilled.A minimal NCS protocol was recommended by
YR based on the neurophysiological criteria of the EFNS/PNS
guideline. Motor nerve examination should include at least the
unilateral forearm part of the median and ulnar nerve and the
foreleg part of the peroneal and tibial nerve. Parameters should
include a CMAP, distal motor latency, distal CMAP duration,
mean conduction velocity, conduction block (CB) and temporal
dispersion (TD) and F-waves. Sensory nerve examination should
include at least two nerves of the upper limb (median, ulnar, or
radial) and one lower limb (sural), registering the sensory nerve
action potential (SNAP) amplitude and sensory nerve conduction
velocity. It was also recognized that in most cases more extensive
protocols are needed to rule out a demyelinating neuropathy but
that in some cases limited studies are sufficient to confirm a
demyelinating neuropathy.As NCS protocols and limits of normal
values for each parameter vary throughout laboratories, a
standardised protocol is needed that includes guidelines on
temperature and distal distances, and use of normative values
(normalization of data in percentages of upper and lower limits of
normal and ratios CMAP/SNAP and CB/TD).
Upload of raw NCS data into any databases directly from
NCS software is currently impossible. Steps to enable transfer
of data will be undertaken, first by contacting EMG
manufacturers.
Collection of other diagnostic data is needed to improve
diagnostic criteria and develop prognostic modelling of
treatment outcome. Except for cerebrospinal fluid results,
uploading of raw data of MRI, ultrasound imaging and biopsies
is challenging, as data files are very large. Therefore, it was
considered sufficient to enter CSF results and information on
whether other diagnostics were performed and whether these
were normal or not. Source data from imaging and biopsies can
be retrieved in a later stage if judged necessary.
6. Biomaterials
6.1. Introduction and overview of collected biomaterials
Biomaterials of interest in CIDP are serum, DNA, RNA,
peripheral blood mononuclear cells (PBMC), CSF, nerve and
skin biopsies. Kathrin Doppler presented the advantages and
disadvantages of central storage versus storage at each
participating centre, as these are the two main infrastructures
currently used in registries. Ivana Basta used an example of
their collection of biomaterials on limb girdle muscular
dystrophies to present the infrastructural possibilities and
challenges in middle-income countries. In these countries
additional funding is often needed for storage and shipment of
biomaterials.
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Luis Querol (LQ) provided an overview on the biomaterials
collected in the registries. At baseline, serum was collected in 5
registries, DNA in 3 registries, with additional materials
collected in the Japanese registry and selected ICOS centres
only. Registries used both central storage and storage at
participating centres. Finally, LQ proposed a modular view to
collection of materials, allowing centres with special scientific
interest to collect biomaterials as judged necessary.
6.2. Consensus on collection of biomaterials
A registry that includes sampling at each visit was regarded as
not feasible for most centres, as this requires a complex
infrastructure. Serum at baseline was considered a minimal
acquirement. Collection of DNA is largely dependent on local
legislation/regulation, and mandatory collection was considered
too complex. Collection of other materials at baseline will be
only performed by centres with specific interest in biomarkers of
disease activity and pathogenesis of CIDP. Storage of materials
at participating centres was preferred above central collection
for various reasons including feasibility in terms of costs, legal
issues (especially on DNA collection), and autonomy of
participating centres to follow different study protocols. The
need of standardised protocols for specimen collection of serum,
CSF and biopsies was again emphasized.
7. Database, governance, legal considerations and funding
7.1. Overview of current databases
Max Adrichem and Luis Querol gave an introduction on
possible registry infrastructures (network topologies),
explaining the advantages and disadvantages of all these
structures. In this overview, software of databases used in the
current registries was compared illustrating how much effort
has already been put in different databases. Different registries
used heterogeneous databases, but this is less important as long
as data can be exported and combined with data from other
databases. Creating a common data dictionary is crucial to
combine data already collected and to harmonize databases in
the feature. Harmonizing case report forms and data entry fields
at question/answer level are necessary to enable a common data
dictionary. Stephen Reddel introduced MSbase, a large global
database that encompasses not only multiple sclerosis but
also other neuroimmunological conditions and suggested
incorporation of CIDP registries into MSbase. Important
advantages would be the established infrastructure of MSbase
and comparison of CIDP to other neuroimmunological
disorders. Alternatively, MSbase is less suitable for more
complex registries. Also, MSbase is governed largely by people
not involved in CIDP research and this was considered a major
disadvantage.
7.2. Patient participation, legal considerations and funding
Patricia Blomkwist reported on the role of the GBS/CIDP
Foundation in other registries such as the International
Guillain–Barre Outcome Study (IGOS) and emphasized how
important such global initiatives are to patient groups. David
Cornblath and Bart Jacobs gave examples of how funding can
be secured, including grant proposals to the GBS/CIDP
Foundation, private parties and pharmaceutical companies.
Many IVIg manufacturers have already provided funding to
current registries such as CSL Behring to ICOS, Kedrion to the
Italian registry and Grifols to the Spanish registry. In a more
global initiative, pharmaceutical companies are considered as
potential partners as these registries can provide data on long-
term treatment efficacy and pharmacovigilance and improve
outcome measures for clinical trials. Finally, Michael Lunn
summarised the upcoming changes in the EU directive on data
sharing. Increasingly, data sharing has become more complex
as there is a narrow balance between privacy regulation and
increasing need for collaboration and big data. In addition, a
global registry should take into consideration the different
legislation and regulations of different countries (i.e. USA
versus the European Union). Legislation and regulations
around data appears to be a very dynamic field, and a new EU
directive providing more clarity on many issues is expected in
2018. Given the complexity of governance of a global database,
close collaboration with data protection officers will be needed.
7.3. Consensus on database
The discussion on databases included the governance and
legal considerations, as these are greatly dependent of each
other. The main advantage of having a central database is more
uniformity, sharing of common objectives in the future but it
comes at a cost of more complex governance. Most participants
therefore preferred a decentralized infrastructure in which
centres use the separate databases that share data with a central
database. Local databases can remain adjustable to provide the
local needs of participating centres and allow centres to
continue ongoing national studies that are already imbedded in
their infrastructure. A decentralized infrastructure requires that
registry protocols are harmonized and that a uniform data
dictionary will be developed to ensure that meaning,
relationships to other data, origin, usage, and format of data-
fields are comparable.
The central database can be used to combine data between
two or more registry databases. New centres that want to
participate can then join existing local registry databases or
enter data directly into the central database. All centres remain
owner of their data and can withdraw these data from the central
registry. A set of requirements was set for a central database that
is summarised in Table 2. As the Inflammatory Neuropathy
Consortium was considered as one of the major driving force
behind this initiative, the name INCbase was suggested for the
central database.
7.4. Consensus on governance and funding
An INCbase Steering Committee (SC) that can govern
INCbase will be established. However, it was decided to install
an INCbase task force first that can elaborate on the newly
formulated objectives before setting up an SC. This task force
has to reach consensus on some open items and has to move
forward many other tasks that lay ahead that require specific
know-how of the currently running registries and databases
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infrastructure, biobank protocols, legislation and funding.
Where INCbase will be centred will depend on these factors,
and this was not addressed at the workshop.
Ongoing funding is one of the crucial requirements for this
project. Funding will be needed for the development and
management of the central INCbase database, management of
databases and biobanks of current registries, monitoring if
required by local legislation and specific projects to analyse
data or biomaterials. The task force will submit grant proposals
for the central database to pharmaceutical companies and
the GBS/CIDP Foundation. The registry coordinators are
responsible for funding of currently running registries. Local
sites will be assisted in the future by the SC to obtain funding
for biobanks and specific research questions.
8. Further steps and timeline
Future steps can be divided into two major categories:
1) Harmonize current registry protocols;
2) Develop INCbase as a central database that interacts with
current registries.
The INCbase task force will consist of the following ENMC
participants: Eftimov (chair first objective), Querol (chair
second objective), Allen, Antoine, Basta, Doppler, Lehmann,
Lunn, Jacobs, Nobile-Orazio, Rajabally and Reddel. In addition
Professor Sobue from Japan agreed to participate in the task
force.
For the first objective there is a need of a detailed
comparison of current registries study protocols, case reports
forms and data entry fields. The task force will advise on
possible adjustment of current protocols, set a minimal core set
for baseline data and create standardised protocols for NCS
studies and data collection, serum, CSF, nerve and skin biopsy
collections. The possibilities of automatic data transfer from
NCS software to other databases will be explored by contacting
NCS hardware and software companies.
For the second objective of choosing a new central registry we
will first request dummy log in accounts to existing databases to
compare advantages and disadvantages. Potential databases will
be screened whether they fulfil the database requirements
summarised in Table 2. Fields required in the central database
need to be defined, allowing also input from more complex
protocols. Database companies and data managers of existing
registries will be contacted to explore the possibilities of creating
a common data dictionary. Similarly, we will contact data
protection officers in different countries (EU/UK/USA/Japan)
and coordinators of other global databases to anticipate expected
changes in legislation. Pharmaceutical companies will be
contacted for funding of INCbase.
9. Timeline
- July 2017: comparison of registries’ data fields and
agreement on minimal core data set for central database
- September 2017:
1) proposal for adjustments of current protocols; and
2) workplan for standardisation of NCS data and samples
collection
- January 2018: secure funding for INCbase; decision on
INCbase database; finalize data dictionary; combine data
from existing registries.
- May 2018: finalize INCbase; enter data of first new patient.
10. Summary
Eight currently ongoing international CIDP registries were
compared to assess infrastructure and collected clinical data,
diagnostic data and biomaterials to enhance future research and
improve standards of care in CIDP.
Consensus was reached on:
- Inclusion criteria: clinical suspicion of CIDP; exclusion
criteria: other diagnoses.
- The need of extensive baseline clinical and diagnostic data
in defining phenotypes but the minimal core of clinical data
is yet to be defined.
- Flexible follow-up visits with preferably at least a 2-year
follow-up. Minimal outcomes during follow-up: a) grip
strength, fatigue, disability (INCAT and iRODS), quality of
life (EuroQol) in all participants and b) impairment outcome
measures based on individual patient characteristic at
physicians discretion.
- A minimal protocol for nerve conduction study was
suggested.
- Collection of biomaterials (serum, CSF, nerve biopsy)
should be according to standardised protocols, with at least
serum collection at baseline. Biomaterials are stored in
participating centres or coordinating centres.
- Infrastructure: a central database (INCbase) will be
developed in which data from existing database can be
uploaded. A set of requirements for INCbase was defined.
Current registries and databases continue to exist.
- All centres remain owner of data and biomaterials and can
withdraw data from INCbase.
Proposed plans:
- Task force to harmonize the current registry protocols and
develop INCbase as a central database.
- The task force has proposed a timeline for the development
and finalization of this registry with a plan to include first




Versatile, can accommodate data from both simple and complex
databases/follow-up
Data from existing registries data can be transferred (after adapting field
definitions/data dictionary)
Allows uploads/downloads and erasure of personal data according to current
and future legislation and fair guide principles (ownership and sharing)
Allows extraction of data at centre level
Graphical interface
Allows upload of digital PROMS questionnaires
Free text possible
Possible expansion to other neuropathies in future
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